HR Execs on the Move

Micro-Precision Technologies

www.micropt.com

 
Micro-Precision Technologies is a Salem, NH-based company in the Computers and Electronics sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Axcelis

Axcelis Technologies, Inc. is a world-leading provider of equipment and services to the semiconductor manufacturing industry. For over forty five years, chipmakers from around the globe have relied on Axcelis` tools and process expertise to form the transistors that power all electronics - from smartphones and laptops, cameras, personal music players and more. Our equipment portfolio comprises a powerful suite of manufacturing technologies for ion implantation, one of the most critical steps in the IC manufacturing process. In addition, we provide extensive aftermarket service and support, including spare parts, equipment upgrades, maintenance services, and customer training. Our customers include all of the 20 largest semiconductor manufacturers in the world. More than 3000 of our products are in use worldwide. At our Advanced Technology Center in Beverly, Mass., we collaborate with customers and other industry experts to develop next-generation applications and process capabilities. We support our customers with a worldwide network of 38 field offices in 10 countries. In all that we do, our strategy is singular: align every Axcelis innovation and success with our customers` goals. We strive to understand the entirety of their challenges and stand ready to deliver the technology, service and support they need to succeed.

Vision Components

Vision Components is a Hudson, NH-based company in the Computers and Electronics sector.

Sidense

Sidense Corp., founded in 2004, is a leading developer of silicon-proven, embedded non-volatile memory (NVM) intellectual property (IP). Sidense`s patented 1T-Fuse™-based one-transistor one-time programmable (1T-OTP) memory enables a wide range of electronic products that are built with complex System-on-Chip (SoC) semiconductors. End-market products include home entertainment consumer products, cellular telephones and other mobile communications devices, configurable processors, RFID, medical, industrial, automotive and a host of others. Semiconductor and systems companies integrate Sidense 1T-OTP IP macros into their SoC designs, saving time and money and allowing them to focus on the core competencies that differentiate their products. Sidense provides memory IP that is difficult and uneconomical for the device makers to try to create on their own. Important requirements of Sidense customers include the need to incorporate NVM that can be manufactured on a standard-logic CMOS process with no additional masks or process steps, is field-programmable, has a very small footprint, very fast read access times, is extremely difficult to reverse engineer, and has very low operating and standby power consumption. Sidense is the only supplier of antifuse 1T-OTP IP that can meet all of these demanding requirements at the leading semiconductor foundries from 180nm to 20nm, with development underway at smaller geometries.

Immedia Semiconductor

Immedia Semiconductor is a Andover, MA-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.